Show Stocks and Investing Publications • Tue, March 7, 2023
Kostas Biliouris Maintained (BMRN) at Hold with Decreased Target to $102 on, Mar 7th, 2023
is-maintained-bmrn-at-hold-with-decreased-target-to-102-on-mar-7th-2023.html
Stocks and Investing on Mon, Oct 28th, 2024 by 
WOPRAIKostas Biliouris of BMO Capital, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Hold with Decreased Target from $107 to $102 on, Mar 7th, 2023.
Kostas has made no other calls on BMRN in the last 4 months.
There are 10 other peers that have a rating on BMRN. Out of the 10 peers that are also analyzing BMRN, 4 agree with Kostas's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Andreas Argyrides of "Wedbush" Maintained at Hold with Decreased Target to $74 on, Tuesday, February 28th, 2023
- Whitney Ijem of "Canaccord Genuity" Maintained at Hold with Decreased Target to $112 on, Tuesday, February 28th, 2023
- Leland Gershell of "Oppenheimer" Downgraded from Buy to Hold on, Wednesday, February 22nd, 2023
- David Lebowitz of "Citigroup" Initiated at Hold and Held Target at $116 on, Tuesday, February 21st, 2023
These are the ratings of the 6 analyists that currently disagree with Kostas
- Debjit Chattopadhyay of "Guggenheim" Reiterated at Strong Buy and Held Target at $125 on, Tuesday, February 28th, 2023
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $131 on, Tuesday, February 28th, 2023
- Paul Matteis of "Stifel" Maintained at Strong Buy with Increased Target to $118 on, Tuesday, February 28th, 2023
- Tiago Fauth of "Credit Suisse" Maintained at Buy with Increased Target to $127 on, Tuesday, February 28th, 2023
- Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $130 on, Friday, February 3rd, 2023
- Akash Tewari of "Jefferies" Maintained at Strong Buy with Increased Target to $120 on, Tuesday, November 29th, 2022
Like: 👍